A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) (NCT07227311)
A Phase 2, Multicenter, Open Label, Non-randomized Study to Evaluate the Efficacy and Safety of Extended Dosing of Belantamab Mafodotin in Different Combinations With Standard of Care Regimens in Participants With Relapsed-refractory Multiple Myeloma (DREAMM-15)
🩺 Plain-English Summary (8th-Grade Level)
This study is for adults with multiple myeloma (a type of blood cancer) that has come back after being treated earlier or isn't responding to the current treatment. The main goal is to find out if the study drug, belantamab mafodotin, given less often (on an extended schedule) with other cancer medicines, can still treat the cancer effectively while causing fewer side effects, especially those affecting the eyes. The study will also look at how well the treatment works overall and how safe it is when administered to the participants.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Los Alamitos, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (59 Sites)
Showing the first 25 of 59 sites.
- GSK Investigational Site — Los Alamitos, California
- GSK Investigational Site — Torrance, California
- GSK Investigational Site — Whittier, California
- GSK Investigational Site — Norwich, Connecticut
- GSK Investigational Site — Fort Myers, Florida
- GSK Investigational Site — Macon, Georgia
- GSK Investigational Site — Baton Rouge, Louisiana
- GSK Investigational Site — Bethesda, Maryland
- GSK Investigational Site — Bridgeton, Missouri
- GSK Investigational Site — Springfield, Missouri
- GSK Investigational Site — Farmington, New Mexico
- GSK Investigational Site — Nashville, Tennessee
- GSK Investigational Site — Dunkirk, Nord
- GSK Investigational Site — Nantes,
- GSK Investigational Site — Paris,
- GSK Investigational Site — Paris,
- GSK Investigational Site — Paris,
- GSK Investigational Site — Saint-Etienne,
- GSK Investigational Site — Frankfurt,
- GSK Investigational Site — Hamburg,
- GSK Investigational Site — Karlsruhe,
- GSK Investigational Site — Koblenz,
- GSK Investigational Site — München,
- GSK Investigational Site — Thessaloniki, Central Macedonia
- GSK Investigational Site — Athens,
📞 Contact the Study Coordinator
Phone: (877) 379-3718
Email: GSKClinicalSupportHD@gsk.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Myeloma
- Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
- Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
- MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
- A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey
Explore by condition: All Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.